Please ensure Javascript is enabled for purposes of website accessibility

Why Moderna Is Rising Today

By Prosper Junior Bakiny - Updated May 12, 2020 at 1:01PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company is ready to move forward with its efforts to develop a vaccine for the coronavirus.

What happened?

Shares of Moderna (MRNA -5.06%) were up by 9.4% as of 3:32 p.m. EDT on Thursday, after the company released its fiscal first-quarter earnings report.

However, the company's actual financial results weren't the highlight of its earnings release. Moderna announced some exciting news regarding its investigational COVID-19 vaccine, mRNA-1273. This news more than likely served as the catalyst for Moderna's shares jumping today.

So what

Moderna has been one of the leaders in the race to develop a vaccine for COVID-19. Back in mid-March, the National Institutes of Health (NIH) started a phase 1 clinical trial to investigate the safety of mRNA-1273, its ability to trigger an immune response in the body, and the amount that causes expected side effects. The trial initially enrolled 45 healthy adult volunteers, but it was later amended to include six additional participants.

A person filling a syringe with liquid from a glass vial

Image source: Getty Images.

On May 9, Moderna announced that the U.S. Food and Drug Administration (FDA) greenlit its Investigational New Drug Application (IND) for mRNA-1273, and the company is moving into phase 2 trials, which will "run in parallel with the NIH-run Phase I study." It expects to begin phase 3 dosing in "early summer."

Now what

Moderna's shares are up by 176.1% year to date thanks to its efforts to develop a vaccine for the coronavirus. And while the biotech company seems to be in a good position to be the first to do so, Moderna's stock remains risky. Moderna's investigational COVID-19 vaccine could still run into negative results from clinical trials -- or for that matter, another company could beat the company in this race. If that happens, Moderna's stock will come crashing down

Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$150.00 (-5.06%) $-8.00

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
397%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/19/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.